Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gecacitinib in Steroid-Refractory/Dependent Active Chronic Graft Versus Host Disease
NCT07476872Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2026
- Primary completion
- Nov 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of jaktinib in chronic graft-versus-host disease (cGVHD), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
jaktinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT07476872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07476872.